{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'applicable data and safety monitoring plan for studies actively enrolling or treating patients.', 'The IRB reviews the study progress and safety information to assess continued acceptability', 'of the risk-benefit ratio for human subjects. Approval of committees as applicable is', 'necessary to continue the study.', 'The trial will comply with the standard guidelines set forth by these regulatory committees', 'and other institutional, state and federal guidelines.', 'Additionally, scheduled meetings will take place weekly and will include the Principal', 'Investigator (Michael Schweizer, MD), research nurse, data manager, and, when appropriate,', 'the collaborators, sub-investigators, and biostatistician involved with the conduct of the', 'protocol.', 'During these meetings the Sub-Investigators/ Principal Investigator will discuss matters', 'related to: safety of protocol participants, validity and integrity of the data, enrollment rate', 'relative to expectation, characteristics of participants, retention of participants, adherence to', 'protocol (potential or real protocol violations), data completeness, and progress of data for', 'secondary objectives.', '10.2.1', 'Source data', 'Source data will be maintained in study binders or electronically in secure servers as', 'appropriate. Servers will be maintained at SCCA/UWMC and any hard copies of source data', 'will be kept in a locked office or locked filling cabinets.', '11.', 'EVALUATION AND CALCULATION OF VARIABLES', 'Prostate cancer has a tendency to metastasize to bone and lymph nodes and is often associated', 'with non-measurable metastatic disease per RECIST 1.1 criteria, even in its later stages [96,', '105]. To maximize patient eligibility, those with non-measurable disease at baseline (per', 'RECIST 1.1) will be permitted to enroll. Because evaluating for objective radiographic', 'response will not be possible in all patients enrolled, we will determine the effects of', 'treatment on PSA. The primary objective of this study will therefore be to determine the', 'proportion of patients with >50% decline in PSA from baseline following initiation of', 'treatment (i.e. PSA50 response rate). As recommended by the PCWG3, this will be assessed', 'following 12-weeks of BAT plus olaparib therapy [95].', '11.1', 'Calculation or derivation of efficacy variable(s)', 'PSA Response: The percent decline in PSA compared to baseline (i.e. most recent PSA value', 'prior to first dose of study drugs) will be calculated for each patient for every on-study PSA', 'value obtained. PSA50 response will be defined as a decline in PSA >50% compared to', 'baseline. The primary objective is to determine the PSA50 response rate (i.e. proportion of', 'patients achieving a PSA50 response) 12-weeks after initiating therapy.', 'PSA Progression: PSA progression will be defined as follows:', '71(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'For subjects showing an initial decline in PSA from baseline, PSA progression will be', 'defined as an increase in PSA that is >25% and >2 ng/mL above the nadir, and which is', 'confirmed by a second value 3 or more weeks later (i.e., a confirmed rising trend).', 'For those subjects with no decline in PSA from baseline, PSA progression will be', 'defined as an increase in PSA that is >25% and >2 ng/mL after 12 weeks.', 'Radiographic Response: RECIST 1.1 guidelines will be used to define measurable, non-', 'measurable, target lesions (TLs) and non-target lesions (NTLs) [96]. Measurable VS. non-', 'measurable lesions will be defined as follows:', 'Measurable lesions - lesions that can be accurately measured in at least one', 'dimension with longest diameter >20 mm using conventional techniques or >10 mm', 'with spiral CT scan.', 'Non-measurable lesions - all other lesions, including small lesions (longest diameter', '<20 mm with conventional techniques or <10 mm with spiral CT scan) and those that', 'can truly not be measured (i.e., bone lesions, leptomeningeal disease, ascites,', 'pleural/pericardial effusion, lymphangitis cutis/pulmonis, cystic lesions, and also', 'abdominal masses that are not confirmed and followed by imaging techniques).', 'All measurements should be taken and recorded in metric notation, using a ruler or calipers. All', 'baseline evaluations should within the 28-day screening period.', 'CT chest/abdomen/pelvis should be used to characterize each identified and reported lesion at', 'baseline and during follow-up. Ideally iodinated contrast should be used, but if this is not', 'possible (e.g. contrast allergy, renal insufficiency), then all subsequent scans should also forgo', 'the use of contrast.', 'Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules', 'and palpable lymph nodes). For the case of skin lesions, documentation by color photography,', 'including a ruler to estimate the size of the lesion, is required.', 'Baseline Documentation of \"Target\" and \"Non-Target\" Lesions', 'All measurable lesions up to a maximum of five lesions per organ and 10 lesions in total,', 'representative of all involved organs, should be identified as target lesions and recorded and', 'measured at baseline.', 'Target lesions should be selected on the basis of their size (lesions with the longest diameter)', 'and their suitability for accurate repeated measurements (either by imaging techniques or', 'clinically).', 'A sum of the longest diameter (LD) for all target lesions will be calculated and reported as the', 'baseline sum LD. The baseline sum LD will be used as reference by which to characterize the', 'objective tumor.', '72(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}